Pfizer Price Targets Rise, but Ratings Stay Unchanged
Four firms lifted Pfizer price targets between October 6 and October 9 without changing their ratings, with targets ranging from $28 to $33. The stock closed at $28.28 on October 9, while consensus 2029 and 2030 revenue estimates moved less than 0.3% since September 30. Analysts pointed to the upcoming quarter and the MEVPRO-1 prostate cancer trial, even as Pfizer’s revenue is projected to decline to about $54 billion by 2030.
Between October 6 and October 9, four banks raised Pfizer targets without changing ratings. JPMorgan moved to $30, BofA to $29, and Cantor to $28, all Neutral; Scotiabank went to $33 while keeping Outperform. The shares closed October 9 at $28.28, up 1.65%.
Since September 30, consensus 2029 and 2030 revenue moved less than 0.3%. Analysts expect 2026 revenue around $62 billion, near the top of Pfizer’s $60.5 billion-$62.5 billion guidance, then roughly $54 billion by 2030. Patent expirations are projected to cut 2026 revenue by about $1.5 billion. BofA linked its increase to a third-quarter preview, while Cantor pointed to the MEVPRO-1 prostate cancer trial.
The unchanged ratings suggest analysts see limited near-term upside, so retail and institutional investors may treat the target increases cautiously. Patients could be affected if pipeline trials and new approvals, such as Tukysa’s breast cancer approval, translate into treatment options, though safety warnings and competition may shape adoption. Pfizer’s projected revenue decline could influence spending on research, manufacturing, and jobs, with possible ripple effects for employees and communities, but the timing and magnitude remain uncertain.